GSE148282 role of exosomal miRNAs in anthracycline-induced liver injury in breast cancer patients

Contributors : Y Zhang ; D Wang ; D Shen ; Y Luo ; Y Q CheSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Homo sapiensAnthracycline-induced liver injury (AILI) is one of the serious complications of anthracycline-based adjuvant chemotherapy for postoperative breast cancer patients. Exosomal miRNAs, as signaling molecules in intercellular communication, play the essential roles in the drug-induced liver injury (DILI). However, the expression profiles of them in patients with AILI remains unknown. Seven post-chemotherapy patients were recruited in this study. After isolated plasma-derived exosomes, small RNA sequencing revealed exosomal miRNA profiles and differentially expressed miRNAs (DE-miRNAs) were identified between the liver injury group and non-liver injury group.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by high throughput sequencing Homo sapiens Source Type: research

Related Links:

AbstractFew millions of new cancer cases are diagnosed worldwide every year. Due to significant progress in understanding cancer biology and developing new therapies, the mortality rates are decreasing with many of patients that can be completely cured. However, vast majority of them require chemotherapy which comes with high medical costs in terms of adverse events, of which cardiotoxicity is one of the most serious and challenging. Anthracyclines (doxorubicin, epirubicin) are a class of cytotoxic agents used in treatment of breast cancer, sarcomas, or hematological malignancies that are associated with high risk of cardi...
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
The immune system plays a fundamental role in the response to neoadjuvant chemotherapy (NAC) of locally advanced breast cancer (LABC) patients. Patients with pathological complete response (pCR) after NAC have a higher survival rate. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) are peripheral blood indicators of inflammatory response. This investigates the correlation between NLR, PLR, LMR, and other clinicopathological features of breast cancer patients before receiving NAC and pCR. Data of LABC patients who underwent NAC between 2009 and 2018 were retro...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Yuan Triple negative breast cancer (TNBC) is an aggressive breast cancer with historically poor outcomes, primarily due to the lack of effective targeted therapies. The tumor molecular heterogeneity of TNBC has been well recognized, yet molecular subtype driven therapy remains lacking. While neoadjuvant anthracycline and taxane-based chemotherapy remains the standard of care for early stage TNBC, the optimal chemotherapy regimen is debatable. The addition of carboplatin to anthracycline, cyclophosphamide, and taxane (ACT) regimen is associated with improved complete pathologic response (pCR). Immune checkpoint inhibit...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionSymptoms of polyneuropathy following adjuvant docetaxel and oxaliplatin persist 5  years after treatment and affect quality of life negatively.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
ConclusionOur findings do not confirm the endoxifen threshold values for TDM nor does it allow definition of a novel threshold. These findings indicate a limited value of TDM to guide tamoxifen efficacy.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionsLess than half of the total number of patients maintained a medium level of overall HRQoL after diagnosis and treatment of breast cancer, and nearly 60% continued to have lower overall HRQoL even after the treatment was complete. Older participants with more severe economic burden and higher depression experienced lower and more persistent overall HRQoL; thus, these patients should be monitored and provided supportive care as a part of survivorship care.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsScreening and management of distress, problems, and referral wish are important, even years after chemotherapy completion as a substantial proportion of breast cancer survivors continue to report elevated distress and problems. Special attention should be paid to survivors reporting physical problems, especially fatigue and lack of physical fitness, since these problems are most strongly related to continuing elevated distress.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Publication date: Available online 28 May 2020Source: Materials Science and Engineering: CAuthor(s): Jing Zhang, Lijia Liang, Zhiyuan Li, Yanting Shen, Xin Guan, Jing Yue, Lili Cong, Weiqing Xu, Wei Shi, Chongyang Liang, Shuping Xu
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Authors: Vasson MP, Kwiatkowski F, Rossary A, Jouvency S, Mouret-Reynier MA, Duclos M, Van Praagh-Doreau I, Travade A, Bignon YJ Abstract A growing knowledge highlights the strong benefit of regular physical activity in the management of breast cancer patients, but few studies have considered biological parameters in their outcomes. In the prospective randomised trial after breast cancer treatment completion "PACThe," we determined the effects of physical activity and nutritional intervention on the biological and anthropometric status of patients after one year of follow-up, and clarified the link betwee...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Abstract In the phase 3 EMBRACA trial, treatment with the poly(ADP-ribose) polymerase inhibitor, talazoparib, led to significantly improved progression-free survival (PFS) compared with chemotherapy (hazard ratio, 0.54; 95% confidence interval, 0.41-0.71; P 12 months were independent covariates associated with longer PFS. The association of talazoparib exposure with PFS (higher exposure, longer PFS) suggests the recommended starting dose of 1 mg once daily (the maximum tolerated dose) is appropriate. PMID: 32468579 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: J Clin Pharmacol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Liver | Study | Urology & Nephrology